Park, Sohee;
Kim, Ju Hwan;
Kim, Songhee;
Kang, Jisu;
Moon, Seoyoung;
Kim, Seok Jin;
Shin, Ju-Young;
(2023)
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study.
Blood Cancer Journal
, 13
, Article 123. 10.1038/s41408-023-00889-5.
Preview |
Text
Park_s41408-023-00889-5.pdf Download (559kB) | Preview |
Abstract
Tisagenlecleucel (tisa-cel) is an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy first approved by the US food and drug administration in 2017 for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least two treatment lines based on the efficacy observed in the JULIET phase 2 single-arm trial (Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients) [1]. Before the introduction of CAR-T therapies, pooled data analysis reported poor objective response rate of 26% and median overall survival (OS) of 6.3 months among patients with r/r DLBCL [2], which indeed appears to be inferior to the 52% and 12 months, respectively, observed in the JULIET study [3]. However, there is a scant data on head-to-head comparison between tisa-cel vs conventional treatments, and only one study by Maziarz et al. to date has demonstrated improved patient survival with tisa-cel using two individual patient data (IPD) from the JULIET study and historical treatment arm [4].
| Type: | Article |
|---|---|
| Title: | Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41408-023-00889-5 |
| Publisher version: | https://doi.org/10.1038/s41408-023-00889-5 |
| Language: | English |
| Additional information: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10174378 |
Archive Staff Only
 |
View Item |
